Search results for: Multi-Indication Medicines
Filter search results
New Publication: Assessing Evidence and Access Associated with NICE HTA Decisions Categorised as “Recommended in Line with Clinical Practice”
6 January 2017
…and ‘optimised’ recommendations. In these instances restrictions are being placed on the use of innovative medicines, and reported in a way that is not readily transparent that this is the…
The Office of Health Economics Becomes a Registered Charity
3 February 2017
…was known about R&D and investment, how to measure quality of life or health status and whether medicines represented value for money. OHE was set up to answer these questions….
OHE at ISPOR Boston 2017: Presentations and Posters
4 July 2017
…the European Union via the centralised procedure (coordinated by the European Medicines Agency); many health care systems in Europe then evaluate new technologies according to their effectiveness and cost effectiveness….
What do Pharmaceuticals Really Cost in the Long Run?
6 October 2017
…Medicines Files for the period ranging from 1996 to 2013. Defining the year of Loss of Exclusivity (LOE) as the first year that a generic National Drug Code was used…
Opportunities for Utilising ‘Real World Data’ in South Korea
20 October 2017
OHE publishes a report assessing the capacity in South Korea for the collection and use of real-world data in health care. Real world data (RWD) is information collected from a…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…and Cures: A Discrete Choice Experiment. OHE Consulting Report, London: Office of Health Economics. RePEc. Marsden, G. and Towse, A., 2017. Exploring the Assessment and Appraisal of Regenerative Medicines and Cell…
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
…in the United States: Pricing and Paying for Cures. OHE Seminar Briefing 25. RePEc. Marsden, G. and Towse, A., 2017. Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products:…
A Final MVAC Blueprint—and the Start of an R&D Revolution?
6 February 2020
…(2019). The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment. OHE Research Paper, London: Office of Health Economics. Available at: https://www.ohe.org/publications/who-technical-report-pricing-cancer-missingcentral-role-hta-and-value-assessment …
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
14 April 2020
…basis of cost-effectiveness principles’. On this basis, there is room for the consideration of novel elements of value to better account for the relative value of new medicines, better align…